MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Firm”), a medical phase pharmaceutical company devoted to extending healthy life-span, today announced that the first individual has actually been signed up in the Business’s Phase 2 scientific trial of lead prospect MYMD-1, an oral immune regulatory authority medicine, as a treatment for delaying aging as well as broadening healthy and balanced lifespan.
The main endpoint for the Stage 2 double-blind, placebo-controlled scientific trial is to attain a reduction in the circulating levels of (TNF-α), growth necrosis element receptor I (TNFRI) and IL-6. TNF-α as well as IL-6 are the proteins in the body that create swelling and also assist activate the process of aging. The second steps of the trial will be the safety and security, tolerability, and also pharmacokinetics in this populace of individuals.
” In a Stage 1 clinical trial of MYMD-1, we demonstrated the drug’s statistically considerable efficiency in decreasing degrees of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has approved TNF-α decrease as the key endpoint for our Phase 2 study, which our company believe positions us well for a successful Phase 2 outcome,” claimed Chris Chapman, M.D., President, Director and also Chief Medical Officer of MyMD. “The initiation of person enrollment in this research advances our mission to slow down the aging process, avoid loss of muscle tissue in aging, limitation frailty, and also extend healthy and balanced lifespan.”
MyMD has actually specified that there are no FDA-approved drugs for treating aging problems and extending healthy and balanced life-span people, a market anticipated to be at least $600 billion by 20251 according to a significant investment financial institution. TNF-α blockers are the most proposed medications by earnings, an international market of approximately $40 billion each year,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would certainly boost life expectancy by one year is worth $38 trillion and by ten years deserves $367 trillion.
Along with aging, MYMD-1’s distinct action in regulating the body immune system as well as dealing with persistent inflammation is being created for the therapy of autoimmune disease, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract disease.
” We intend to start creating protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing frequency of rheumatoid arthritis and other autoimmune and also inflammatory illness are driving need for TNF preventions like MYMD-1, and also our company believe our orally administered drug with extremely low toxicity would be disruptive to the $60 billion market for RA if accepted by the FDA for this indication.”
Rheumatoid joint inflammation affects about 40 million individuals around the world.4.
Initially developed for autoimmune conditions, MYMD-1’s primary function is to slow down the aging process, prevent sarcopenia and also frailty, and also extend healthy life expectancy. Because it can go across the blood-brain barrier as well as gain access to the main nerve system (CNS), MYMD-1 is additionally placed to be a possible therapy for brain-related disorders. Its device of activity as well as efficacy in conditions consisting of multiple sclerosis (MS) and also thyroiditis have actually been researched via cooperations with several academic establishments. MYMD-1 is likewise showing pledge in pre-clinical research studies as a prospective therapy for blog post- COVID-19 issues and as an anti-fibrotic as well as anti-proliferation healing.
MYMD-1 has revealed effectiveness in pre-clinical researches in regulating the body immune system by performing as a discerning prevention of tumor death factor-alpha (TNF-α), a motorist of persistent swelling. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical studies to selectively block TNF-α when it comes to be overactivated in autoimmune illness and cytokine tornados, but not block it from doing its typical job of being an initial responder to any routine type of moderate infection. MYMD-1’s convenience of dental application is an additional differentiator compared to currently offered TNF-α blockers, every one of which call for delivery by shot or mixture. No approved TNF prevention has ever been dosed orally. On top of that, the drug is not immunosuppressive and has not been revealed to create the serious negative effects common with standard therapies that deal with inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical company devoted to extending healthy life-span, is focused on creating 2 novel healing systems that treat the causes of disease as opposed to only resolving the signs. MYMD-1 is a medication system based on a clinical stage little molecule that controls the body immune system to regulate TNF-α, which drives chronic swelling, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost long life, as well as deal with autoimmune illness as well as COVID-19- associated anxiety. The Company’s 2nd drug system, Supera-CBD, is being created to treat chronic pain, addiction as well as epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and is being created to attend to as well as surpass the quickly expanding CBD market, that includes both FDA approved medications and also CBD items not presently managed as drugs. For more information, browse through www.mymd.com.